Most Read Articles
4 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
5 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Tradipitant shows therapeutic potential in patients with gastroparesis

03 Aug 2020

Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.

In total, 152 adult patients were randomized to receive oral tradipitant (85 mg; n=77) or placebo (n=75) twice daily for 4 weeks. Researchers assessed symptoms using a daily symptom dairy, gastroparesis cardinal symptom index scores, and other patient-reported questionnaires.

At baseline, nausea severity score was moderate to severe at 3.21, and the percentage of nausea-free days was 7.56 percent. Average scores of other core gastroparesis symptoms were moderate to severe in degree, although not every patient presented with all symptoms.

Four weeks of tradipitant vs placebo led to a significant reduction in average nausea severity (–1.2 vs –0.7; p=0.0099) and an increase in nausea-free days (28.8 percent vs 15.0 percent; p=0.0160). The effects were greater among patients with nausea and vomiting at baseline (n=101; nausea severity: p<0.0001; nausea-free days; p=0.0003).

Average nausea score was 1 at week 4 in 32.9 percent of patients in the tradipitant group as opposed to 11.8 percent of those in the placebo group (p=0.0013). Finally, 46.6 percent and 23.5 percent of patients in the respective groups achieved >1-point improvement in gastroparesis cardinal symptom index score (p=0.0053).

Tradipitant was well tolerated, with an adverse event profile similar to placebo.

According to the researchers, the benefits conferred by tradipitant for nausea and overall symptoms may be indicative of a disease-modifying effect through an action to the local neuromuscular network, as well as the central nervous system centres for nausea and vomiting.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
5 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.